Leflunomide medac is an approved medication utilized for the management of certain autoimmune conditions in adults. It is indicated for the treatment of active rheumatoid arthritis (RA), which is a chronic condition causing inflammation of the joints. For patients with RA, this medication may help to reduce the signs and symptoms of the condition.

The drug is also indicated for the treatment of active psoriatic arthritis (PsA). PsA is a type of inflammatory arthritis associated with the skin condition psoriasis.

Treatment with this medication may help to improve physical function and may slow the progression of structural damage associated with these arthritic conditions. Leflunomide is indicated for adult patients with these active conditions as a disease-modifying antirheumatic drug (DMARD). Consult with a specialist for appropriate usage of this therapeutic option.

---

Quick Facts: Therapeutic Domain

• Active Rheumatoid Arthritis: May help manage signs and symptoms.
• Active Psoriatic Arthritis: May help manage joint inflammation.
• Benefits: May help improve physical function and may slow the progression of joint damage.

Regulatory References

1. EMA therapeutic overview

Leflunomide medac is indicated only for the treatment of adult patients (18 years and older) with active rheumatoid arthritis or active psoriatic arthritis. Use is not recommended for the pediatric population (below 18 years) as regulatory efficacy and safety have not been established in Juvenile Rheumatoid Arthritis. No routine dose adjustment is required for older adults (over 65 years).

The medicine is strictly contraindicated (must not be used) in several patient populations, based on official regulatory labeling:

Contraindicated Population	Specific Eligibility Status
Reproductive Status	Prohibited for pregnant women, breastfeeding women, and women of childbearing potential not using reliable contraception.
Organ Function	Contraindicated in patients with severe hepatic impairment or moderate to severe renal insufficiency.
Immune/Blood Health	Contraindicated in patients with severe immunodeficiency states (e.g., AIDS), serious infections, or significantly impaired bone marrow function.
Comorbidities	Contraindicated with severe hypoproteinaemia and known hypersensitivity to leflunomide or its active metabolite.

Additionally, men wishing to father a child should consider discontinuing treatment and undergoing a drug elimination procedure, as specified by regulatory documents. The use of this medicine is confined to a specific, health-vetted adult patient population.

Interactions with other medicines and products

The official interaction profile for leflunomide is governed by the long persistence of its active metabolite ( A771726) in the body, which dictates specific regulatory constraints for co-administration with other medicines and products.

Interaction Classifications

Classification	Interacting Entity
Formally Contraindicated	Teriflunomide (due to excessive metabolite exposure) and Live Vaccines (due to immunosuppression).
Use Not Advisable	Hepatotoxic DMARDs (e.g., Methotrexate) and other Hepatotoxic Medicinal Products (risk of additive organ toxicity).

Documented Pharmacokinetic Effects

The active metabolite is documented as an inhibitor of the enzyme CYP2C9, potentially increasing the plasma concentrations of co-administered medicines that are metabolized by this pathway, such as Warfarin and Phenytoin. Furthermore, the active metabolite is officially documented to inhibit drug transporters including OATP1B1/1B3 and BCRP, which may increase the exposure of substrates for these transporters.

Rifampin co-administration is noted to increase the peak plasma level ( Cmax) of the active metabolite by approximately 40%.

Procedural and Substance Constraints

• Accelerated Elimination: Regulatory documents mandate a washout procedure using Cholestyramine or Activated Charcoal to rapidly reduce plasma levels of the active metabolite. This procedure is required before switching to another DMARD to mitigate the risk of additive toxicity.
• Substances: The consumption of alcohol is documented to increase the risk of hepatotoxicity (liver damage). Food does not affect the extent of leflunomide absorption.

Population Notes

The interaction risk is noted to be intensified in patients with severe hypoproteinaemia, where plasma levels of the active metabolite are expected to be increased. Additionally, patients aged 60 years or older or with Diabetes taking neurotoxic medications are officially noted to have an increased risk for peripheral neuropathy.

The drug's mechanism involves action at the molecular level that modifies key enzyme activity within specific biochemical pathways. Its mechanism involves a series of steps that limit the proliferation of specific immune cells.

Blocking Essential Building Blocks

The primary mechanism involves the drug's active form, teriflunomide, acting as an inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH). DHODH is necessary for the de novo synthesis of pyrimidines, which are essential components for building DNA and RNA. By blocking this enzyme, the drug limits the supply of these building blocks, which are critical for cell division.

Suppressing Immune Cell Proliferation

The proliferation of specific immune cells, particularly T-lymphocytes, depends on the DHODH pathway. Interruption of this pathway results in decreased proliferation of these cells, leading to a reduction in their numbers. This suppression of immune cell proliferation is the core physiological change that contributes to the drug's overall systemic effect.

How Leflunomide medac is Used

Leflunomide medac is a prescription-only medication that is exclusively administered via the oral route (by mouth). Treatment should be initiated and supervised by specialists experienced in managing inflammatory arthritis.

Official Administration and Dosage Regimen

The medication is available as a film-coated tablet and is typically used in a two-phase regimen: an initial loading dose followed by a daily maintenance dose. The tablets must be swallowed whole with sufficient liquid and can be taken with or without food (absorption is not significantly affected by meals).

Dosing Schedule for Adults

Phase	Indication	Recommended Dose	Notes
Loading	All Approved Indications	100 mg once daily for 3 days	May be omitted in high-risk patients.
Maintenance	Active Rheumatoid Arthritis (RA)	10 mg to 20 mg once daily	The maximum daily dose is 20 mg.
Maintenance	Active Psoriatic Arthritis (PsA)	20 mg once daily

Use Patterns and Adjustments

Leflunomide medac is intended for long-term chronic management of these conditions. The onset of therapeutic effect typically appears after 4 to 6 weeks of treatment.

Population-Specific Guidance:

• Older Adults (Age ge 65): No specific dosage adjustment is required based on age.
• Pediatric Patients (Under 18 years): Use is not recommended as efficacy and safety have not been established in this age group.
• Mild Renal Impairment: No dose adjustment is generally recommended.

Research evidence / Overview of studies for Leflunomide medac

Evidence for use in Active Rheumatoid Arthritis (RA)

Research for leflunomide was studied for use in active Rheumatoid Arthritis (RA), one of the conditions characterized by fluctuating or episodic manifestations. The evidence primarily comes from short-term and intermediate-term randomized controlled trials (RCTs). These studies were designed to research examined how outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level evolved in adult patients. Findings describe patterns observed in the studies over the course of treatment, and research describes changes measured during the study period when compared to a placebo. Systematic reviews synthesizing these RCTs contribute to the broader evidence landscape, suggesting consistency in the reported observations across different international settings.

Evidence for use in Active Psoriatic Arthritis (PsA)

Studies for this medicine were evaluated in adult patients with active Psoriatic Arthritis (PsA), a condition involving periods of heightened symptoms and associated with functional limitations. Primary studies involved randomized controlled trials where the medicine was evaluated in settings with varying symptom burdens, focusing on patient-reported outcomes describing perceived discomfort and specific skin symptom indices. Studies report how symptoms evolved in the observed populations when the medicine was evaluated in comparison to a placebo group.

Long-term Studies and Areas of Uncertainty

While the primary findings were often established in trials lasting six months to one year, researchers also conducted open-label extension studies, with some cohorts observing responses over defined time intervals for up to five years. These studies primarily monitored the long-term patterns observed in the studies in physical function. However, the long-term effects are not fully established beyond the observation periods of these specific studies, and certainty remains low regarding outcomes lasting decades. Follow-up durations were limited in comparison to the long-term nature of the conditions, meaning the long-term outcomes of the treatment is still emerging. Furthermore, the results apply only to the populations studied, and the generalizability of findings to the entire population remains a limitation noted by regulators.

Key Studies & References

1. Leflunomide for the treatment of rheumatoid arthritis - Cochrane Database of Systematic Reviews
2. Rheumatoid arthritis in adults: management (NG100) - NICE Guideline

Common questions about Leflunomide medac (FAQ)

---

Q: What is Leflunomide medac used for?

Leflunomide medac is a medicine authorized for the treatment of rheumatoid arthritis in adults. It is also approved to treat active psoriatic arthritis in adults. According to the official regulatory product information, it is indicated to reduce the signs and symptoms of these chronic inflammatory joint diseases.

---

Q: How does Leflunomide medac work?

Leflunomide medac is classified as a Disease-Modifying Anti-Rheumatic Drug (DMARD). Studies and official information indicate that it acts by affecting the body's immune system. This mechanism is intended to help reduce inflammation and other effects associated with the autoimmune disease.

---

Q: When should I expect to see the effects of Leflunomide medac?

Regulatory documents state that the onset of action for Leflunomide medac is typically gradual. It may take several weeks or even months before the full therapeutic benefit is observed. For this medication, the greatest benefit is typically observed after consistent use as directed.

---

Q: What should I do if I miss a dose of Leflunomide medac?

Official product information describes the procedure for a missed dose: if a dose is missed, it can be taken as soon as the lapse is noticed, unless it is close to the next scheduled dose. The labeling advises that the regular dosing schedule should then be resumed, and a double dose is not recommended to compensate for the missed one.

---

Q: Can Leflunomide medac affect my liver?

Yes, regulatory documents mention that treatment with Leflunomide medac can be associated with changes in liver enzymes (transaminases). Because of this potential, regular blood tests are required to monitor liver function while using this treatment. These tests are conducted to monitor for potential changes in liver function according to the product's safety information.

---

Q: Can I take Leflunomide medac if I am planning to become pregnant?

The official product information strongly states that this medicine is contraindicated during pregnancy due to the risk of fetal harm. Official prescribing information requires women of childbearing potential to use effective contraception throughout treatment and for a specific timeframe after stopping the medication. Detailed guidance on pregnancy planning and procedures like the 'washout' is outlined in the product information and should be reviewed by a qualified healthcare provider.

---

Q: What happens after I stop taking Leflunomide medac?

Leflunomide medac and its active metabolite can remain in the body for a long time following the cessation of therapy. Regulatory documents describe a drug elimination procedure, sometimes referred to as a 'washout' procedure, involving medication like cholestyramine. This procedure is outlined in the product information as a method to support the removal of the active substance, particularly when pregnancy is planned or if certain side effects occur.

Storage and Disposal Requirements

Leflunomide tablets must be stored at Controlled Room Temperature (20 C to 25 C), away from excess heat, light, and moisture. It is required to keep the tablets from freezing. The medicine must remain in the original container, and the container must be kept tightly closed to protect it from moisture.

For child safety, the product must be kept out of the sight and reach of children and should be stored locked up.

Expired or unused product should not be discarded in household waste or wastewater. Disposal must strictly follow applicable regional, national, and local laws and regulations for medicinal products, often requiring consultation with a pharmacist.